- Visibility 103 Views
- Downloads 105 Downloads
- Permissions
- DOI 10.18231/j.ijced.13781.1758884719
-
CrossMark
Chronic graft versus host disease: A case series providing diagnostic and therapeutic perspectives
- Author Details:
-
Monika Kumari
-
Kingshuk Chatterjee
-
Arun Achar
-
Adityendu Chakraborty
-
Sayoni Ghosh
-
Mahormi Mazumder
-
Sadia Rifat
Monika Kumari
Kingshuk Chatterjee
Arun Achar
Adityendu Chakraborty
Background: Chronic graft-versus-host disease (cGVHD) is a complex and serious complication that can arise following allogeneic hematopoietic stem cell transplantation (HSCT), leading to significant morbidity. It presents with diverse clinical patterns and can show marked variability depending on the underlying malignancy of the transplant recipient.
This case series aims to provide insight into the clinical characteristics, histopathological findings, and treatment outcomes of patients diagnosed with cGVHD according to the NIH consensus criteria.
Materials and Methods: A retrospective analysis was conducted on five patients with cGVHD who visited from January 2024 to January 2025. Among the patients, two were diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), one patient with large cell lymphoma, another one with acute myeloblastic leukemia presented exhibited lichenoid-type cGVHD, while one patient with B-ALL mixed-type cGVHD. Comprehensive clinical evaluations and histopathological assessments were performed for each patient.
Results: Two patients with B-ALL, one patient with anaplastic large cell lymphoma and another one patient with AML displayed lichenoid-type cGVHD, characterized by symptoms including a pruritic rash and mucosal involvement, confirmed by skin biopsy findings.
One patient with B-ALL demonstrated mixed-type cGVHD, exhibiting features of both lichenoid and vitiligo types.
All patients were started on immunosuppressive drugs, including corticosteroids and additional targeted therapies. By the latest follow-up, three patients showed substantial improvement in their symptoms; however, one patient required continuous modification of their treatment due to persistent cGVHD manifestations. One patient lost to follow up.
Conclusion: This case series illustrates distinct manifestations of cGVHD in patients with different underlying malignancies, underscoring the importance of tailoring treatment strategies. Early recognition and appropriate management are essential for enhancing patient quality of life in those affected by cGVHD.
References
- Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med . 2010;363(22):2091–101.
- Jaglowski SM, Devine SM. Graft-Versus-Host Disease: Why Have We Not Made More Progress? Curr Opin Hematol. 2014;21(2):141–7.
- Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring Therapeutic Response in Chronic Graft-Versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus- Host Disease: IV. The 2014 Response Criteria Working Group Report. Biol. Blood Marrow Transplant. 2015;21(6):984–99.
- Shlomchik WD. Graft-Versus-Host Disease. Nat Rev Immunol. 2007;7(5):340–52.
- Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, et al. Toward Biomarkers for Chronic Graft-Versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12(2):126–37.
- Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, Andre V, et al. Interleukin-17–Producing T-Helper Cells as New Potential Players Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. Transplantation. 2009;88(11):1261–72.
- Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-Reported Quality of Life Is Associated with Severity of Chronic Graft-Versus-Host Disease as Measured by NIH Criteria: Report on Baseline Data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651–7.
- Pidala J, Sarwal M, Roedder S, Lee SJ. Biologic Markers of Chronic GVHD. Bone Marrow Transplant. 2014;49(3):324–31.
- Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and Management of Graft-Versus- Host Disease after Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157–67.
- Murali AR, Chandra S, Stewart Z, Blazar BR, Farooq U, Ince MN, et al. Graft-Versus-Host Disease after Liver Transplantation in Adults: A Case Series, Review of Literature, and an Approach to Management. Transplantation. 2016;100(12):2661–70.
- de la Rosa-Garcia E, Bologna-Molina R, Vega-Gonzalez MT, De Jesus T. Graft-Versus-Host Disease: An Eight Case Report and Literature Review. Med Oral Patol Oral Cir Bucal. 2006;11(5):E486–92.
- Yong SS, Han WH, Choong RK, Faheem NA, Toh YF, Bee PC, et al. Case Series of Cutaneous Graft-Versus-Host Disease (GVHD) in Patients Receiving Haematopoietic Stem Cell Transplantation in a Tertiary Malaysian Hospital. Hong Kong J Dermatol Venereol. 2023;31(1):5–13.
- Shreberk-Hassidim R, Neumark M, Greenberger S, Goldstein G, Hassidim A, Dukler Y, et al. Cutaneous Chronic Graft-Versus- Host Disease Following Allogeneic Haematopoietic Stem Cell Transplantation in Children: A Retrospective Study. Acta Derm Venereol. 2018;98(2):206–11.
- Yang JS, Park HJ, Lee JY, Kang CS, Kim CC, Cho BK. Chronic Cutaneous Graft-Versus-Host Disease: Clinicopathologic Study. Korean J. Dermatol. 2003;41:187–96.
- Shubert MM, Sullivan KM, Morton TH, Izutu KT, Peterson DE, Flournoy N, et al. Oral Manifestations of Chronic Graft-Versus- Host Disease. Arch Intern Med. 1984;144(8):1591–5.
- Kim SJ, Choi JM, Kim JE, Cho BK, Kim DW, Park HJ. Clinicopathologic Characteristics of Cutaneous Chronic Graft‐ Versus‐Host Diseases: A Retrospective Study in Korean Patients. Int J Dermatol. 2010;49(12):1386–92.
- Ruutu T, Van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, et al. Prophylaxis and Treatment of GVHD after Allogeneic Haematopoietic SCT: A Survey of Centre Strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(11):1459–64.